The level of oestradiol can influence the results of egg donation treatments
The biologist Cristina de la Cruz Rodrigo has conducted a retrospective study that included 535 cycles of egg donation in which 6 or more oocytes have been devitrified. Two groups were compared: the group of vitrification / devitrification cycles with a high oocyte survival rate (> 60%) with the group of vitrification / devitrification cycles with a low oocyte survival rate (≤60%).
To this end, the following main parameters have been analysed: clinical pregnancy rate, live birth rate and abortion rate. Secondary parameters have been analysed: donor age, body mass index, antral follicle count (AFC), antimulerian hormone (AMH) level, type of ovarian stimulation treatment and characteristics of embryonic development.
89% of treatments (476/535) had oocyte survival greater than 60% compared to 11% of treatments (56/535) that had an oocyte survival less than or equal to 60%. The results showed that there were no statistically significant differences in the demographic characteristics of the donor, except for the level of oestradiol on the day of the ovulatory discharge, nor in the type of stimulation treatment. Regarding the results obtained in the laboratory between both groups: fertilization rate (76% vs 71.2%), evolutionary embryo rate (52.3% vs 53.3%) and rate of good quality embryos (28, 6% vs 22.1%), no statistically significant differences were observed. On the other hand, statistically significant differences were observed in the pregnancy rate (46.4% vs 30.5%) and live birth rate (35.9% vs 20.3%), although not in the abortion rate (20.8% vs. 22.2%).
Therefore, the results of the study show that in both groups the results obtained in the laboratory are similar, but when assessing the success of the treatment there are differences. The authors conclude that the higher level of oestradiol on the day of oocyte extraction in the group of low oocyte survival after devitrification, could influence the quality of the ovules, and, therefore, affect the rate of pregnancy and born alive.
C. de la Cruz Rodrigo1, M. Solé1, I. González1, E. Clua1, S. García2, M. Boada1, P.N. Barri1, A. Veiga13.
1 Reproductive Medicine Service, Dexeus Mujer - Dexeus University Hospital, Barcelona, Spain.
2 Unit of Biostatistics, Dexeus Mujer - Dexeus University Hospital, Barcelona, Spain.
3 Barcelona Stem Cell Bank, Center of Regenerative Medicine, Barcelona, Spain.